CoChat
Sign Up
Cited by 4PARP inhibition in cancer therapyBRCA gene mutations in cancerAdvanced Breast Cancer Therapies

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Clinical Use of PARP Inhibitors in BRCA Mutant and Non-BRCA Mutant Breast Cancer

Lynce, Filipa, Robson, Mark·2023·Cancer Treatment and Research
DOI 10.1007/978-3-031-30065-3_6
Open this paper in CoChat — free account

Abstract

The use of poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of patients with germline BRCA mutations (gBRCAm) and breast cancer, both in the early and advanced settings, is a success of genomically-directed treatment. These agents have been shown to be associated with longer progression-free survival when compared to standard chemotherapy, with an acceptable toxicity profile. A recent randomized trial demonstrated improved survival with the use of olaparib for 2 years compared to placebo in patients with early-stage high risk gBRCAm associated breast cancer. Ongoing research efforts are focused on identifying patients beyond those with BRCA1/2 or PALB2 mutations who may benefit from PARP inhibitors, exploring the overlapping mechanisms of resistance between platinum and PARP inhibitors and developing agents with less toxicity that will allow combinational strategies.

Overview

Integrity signals

Registry

Crossref · 10.1007/978-3-031-30065-3_6

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 33

  1. Couch FJ, Nathanson KL, Offit K (2014) Two decades after BRCA: setting paradigms in personalized cancer care and prevention. Science 343:1466–1470 · DOI
  2. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E et al (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434:913–917 · DOI · Paper page
  3. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB et al (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434:917–921 · DOI · Paper page
  4. O’Shaughnessy J, Osborne C, Pippen JE, Yoffe M, Patt D, Rocha C et al (2011) Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 364:205–214 · DOI · Paper page
  5. O’Shaughnessy J, Schwartzberg L, Danso MA, Miller KD, Rugo HS, Neubauer M et al (2014) Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer. J Clin Oncol 32:3840–3847 · DOI · Paper page
  6. Patel AG, De Lorenzo SB, Flatten KS, Poirier GG, Kaufmann SH (2012) Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro. Clin Cancer Res 18:1655–1662 · DOI
  7. Chuang HC, Kapuriya N, Kulp SK, Chen CS, Shapiro CL (2012) Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells. Breast Cancer Res Treat 134:649–659 · DOI
  8. Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N et al (2017) Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med 377:523–533 · DOI · Paper page
  9. Robson ME, Im SA, Senkus E, Xu B, Domchek SM, Masuda N et al (2023) OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Eur J Cancer 184:39–47 · DOI
  10. Robson M, Ruddy KJ, Im SA, Senkus E, Xu B, Domchek SM et al (2019) Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial. Eur J Cancer 120:20–30 · DOI
  11. Litton JK, Rugo HS, Ettl J, Hurvitz SA, Goncalves A, Lee KH et al (2018) Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. N Engl J Med 379:753–763 · DOI · Paper page
  12. Ettl J, Quek RGW, Lee KH, Rugo HS, Hurvitz S, Goncalves A et al (2018) Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial. Ann Oncol 29:1939–1947 · DOI
  13. Litton JK, Hurvitz SA, Mina LA, Rugo HS, Lee KH, Goncalves A et al (2020) Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Ann Oncol 31:1526–1535 · DOI
  14. Dieras V, Han HS, Kaufman B, Wildiers H, Friedlander M, Ayoub JP et al (2020) Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 21:1269–1282 · DOI
  15. Telli ML (2020) BROCADE3: a challenge to the treatment paradigm in BRCA breast cancer? Lancet Oncol 21:1254–1255 · DOI
  16. Tung N, Garber JE (2022) PARP inhibition in breast cancer: progress made and future hopes. NPJ Breast Cancer. 8:47 · DOI
  17. Domchek SM, Postel-Vinay S, Im SA, Park YH, Delord JP, Italiano A et al (2020) Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study. Lancet Oncol 21:1155–1164 · DOI
  18. Vinayak S, Tolaney SM, Schwartzberg L, Mita M, McCann G, Tan AR et al (2019) Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer. JAMA Oncol 5:1132–1140 · DOI
  19. Schram AM, Colombo N, Arrowsmith E, Narayan V, Yonemori K, Scambia G et al (2023) Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors: Results From JAVELIN BRCA/ATM, an Open-Label, Multicenter, Phase 2b. Tumor-Agnostic Trial. JAMA Oncol. 9:29–39 · DOI
  20. Litton JK, Scoggins M, Ramirez DL, Murthy RK, Whitman GJ, Hess KR et al (2017) A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline BRCA mutation demonstrates marked activity. NPJ Breast Cancer. 3:49 · DOI
  21. Litton JK, Scoggins ME, Hess KR, Adrada BE, Murthy RK, Damodaran S et al (2020) Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant. J Clin Oncol 38:388–394 · DOI
  22. Litton JK, Beck JT, Jones JM, Andersen J, Blum JL, Mina LA et al (2021) Neoadjuvant talazoparib in patients with germline BRCA1/2 (gBRCA1/2) mutation-positive, early HER2-negative breast cancer (BC): Results of a phase 2 study [abstract]. J Clin Oncol 39:505 · DOI
  23. Spring LM, Han H, Liu MC, Hamilton E, Irie H, Santa-Maria CA et al (2022) Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer. Nat Cancer. 3:927–931 · DOI
  24. Geyer CE Jr, Garber JE, Gelber RD, Yothers G, Taboada M, Ross L et al (2022) Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Ann Oncol 33:1250–1268 · DOI
  25. Vliek S, Jager A, Jonge-Lavrencic M, Lotz JP, Goncalves A, Graeser M, et al. Substantially improving the cure rate of high-risk BRCA1-like breast cancer patients with personalized therapy (SUBITO) - an international randomized phase III trial [abstract]. Cancer Res. 2018;78:OT2–07–8. · DOI
  26. Tung NM, Robson ME, Ventz S, Santa-Maria CA, Nanda R, Marcom PK et al (2020) TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes. J Clin Oncol 38:4274–4282 · DOI
  27. Gruber JJ, Afghahi A, Timms K, DeWees A, Gross W, Aushev VN et al (2022) A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes. Nat Cancer. 3:1181–1191 · DOI
  28. Sammons SL, Tan TJ, Im Y-H, Traina T, Anders C, Renzulli E, et al. PD11–12 DORA: A Phase II, Multicenter, International, Non-Comparator Study of Olaparib (O) +/- Durvalumab (D) as a chemotherapy-free maintenance strategy in Platinum tReated Advanced Triple-Negative Breast Cancer (aTNBC) [abstract]. Cancer Res. 2023;83:PD11–2. · DOI
  29. Loibl S, O’Shaughnessy J, Untch M, Sikov WM, Rugo HS, McKee MD et al (2018) Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncol 19:497–509 · DOI
  30. Geyer CE, Sikov WM, Huober J, Rugo HS, Wolmark N, O’Shaughnessy J et al (2022) Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial. Ann Oncol 33:384–394 · DOI
  31. Fasching PA, Link T, Hauke J, Seither F, Jackisch C, Klare P et al (2021) Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study). Ann Oncol 32:49–57 · DOI
  32. Fasching PA, Schmatloch S, Hauke J, Rey J, Jackisch C, Klare P, et al. Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency – long-term survival of the GeparOLA study [abstract]. Cancer Res. 2023;83:P4–06–13. · DOI
  33. Michmerhuizen AR, Pesch AM, Moubadder L, Chandler BC, Wilder-Romans K, Cameron M et al (2019) PARP1 Inhibition Radiosensitizes Models of Inflammatory Breast Cancer to Ionizing Radiation. Mol Cancer Ther 18:2063–2073 · DOI

Cited by

Sorted by citations

Metadata

Authors
Lynce, F., & Robson, M.
Affiliations
  • Harvard University (US)
  • Memorial Sloan Kettering Cancer Center (US)
Corresponding author
Lynce, Filipa
ORCID
Venue
Cancer Treatment and Research
Publisher
Springer International Publishing
Published
2023
Volume
186
Pages
91-102
ISSN
  • 0927-3042 (ISSN-L)
  • 2509-8497
DOI
10.1007/978-3-031-30065-3_6
OpenAlex
W4388778438
Cited by
4
References
1
Citations by year
2026: 1 · 2025: 1 · 2024: 2
FWCI
2.80
Type
book chapter
Language
en
Open access
closed
Licence
Locations
  • Cancer treatment and research (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
  • Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
Keywords
PARP inhibitors, germline BRCA mutation, breast cancer, olaparib, progression-free survival, PALB2, platinum resistance, PARP inhibitor resistance, targeted therapy, combination therapy
MeSH terms
Poly(ADP-ribose) Polymerase Inhibitors, Breast Neoplasms, Female, Humans, Ovarian Neoplasms, Poly(ADP-ribose) Polymerases, BRCA1 Protein, BRCA2 Protein

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review